ASCO 2019: 12-Weekly Bone Targeting Agent Schedule Measures Up to 4-Weekly Schedule for Bone Metastases
Findings suggest it is reasonable to de-escalate bone-targeting agents while awaiting results of REDUSE
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.